Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The company's lead product candidate, LN-144, is an adoptive cell therapy that utilizes tumor-infiltrating lymphocytes (TILs) to treat patients with refractory metastatic melanoma. Iovance is also developing TIL therapies for the treatment of cervical, head and neck, and non-small cell lung cancers. The company was founded in 2007 and is headquartered in San Carlos, California.